Imara Inc.to sell IMR 687 to Cadurion Pharma.
IMARA Inc., entered into an Asset Purchase Agreement with Cardurion Pharmaceuticals, Inc., providing for the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program
In addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront cash payment of $34,750,000 upon closing of the transaction and a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms of the Asset Purchase Agreement.